These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 18330212)
1. Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans. Nikolaus S; Antke C; Kley K; Poeppel TD; Hautzel H; Schmidt D; Müller HW Rev Neurosci; 2007; 18(6):439-72. PubMed ID: 18330212 [TBL] [Abstract][Full Text] [Related]
2. In vivo imaging of synaptic function in the central nervous system: I. Movement disorders and dementia. Nikolaus S; Antke C; Müller HW Behav Brain Res; 2009 Dec; 204(1):1-31. PubMed ID: 19523490 [TBL] [Abstract][Full Text] [Related]
3. Investigating the dopaminergic synapse in vivo. II. Molecular imaging studies in small laboratory animals. Nikolaus S; Larisch R; Beu M; Antke C; Kley K; Forutan F; Wirrwar A; Müller HW Rev Neurosci; 2007; 18(6):473-504. PubMed ID: 18330213 [TBL] [Abstract][Full Text] [Related]
4. In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. Nikolaus S; Antke C; Müller HW Behav Brain Res; 2009 Dec; 204(1):32-66. PubMed ID: 19523495 [TBL] [Abstract][Full Text] [Related]
5. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Cummings JL; Henchcliffe C; Schaier S; Simuni T; Waxman A; Kemp P Brain; 2011 Nov; 134(Pt 11):3146-66. PubMed ID: 21810889 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological challenge and synaptic response - assessing dopaminergic function in the rat striatum with small animal single-photon emission computed tomography (SPECT) and positron emission tomography (PET). Nikolaus S; Larisch R; Vosberg H; Beu M; Wirrwar A; Antke C; Kley K; Silva MA; Huston JP; Müller HW Rev Neurosci; 2011; 22(6):625-45. PubMed ID: 22103308 [TBL] [Abstract][Full Text] [Related]
7. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Mehler-Wex C; Riederer P; Gerlach M Neurotox Res; 2006 Dec; 10(3-4):167-79. PubMed ID: 17197367 [TBL] [Abstract][Full Text] [Related]
8. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Ginovart N; Lundin A; Farde L; Halldin C; Bäckman L; Swahn CG; Pauli S; Sedvall G Brain; 1997 Mar; 120 ( Pt 3)():503-14. PubMed ID: 9126061 [TBL] [Abstract][Full Text] [Related]
9. Normal database of dopaminergic neurotransmission system in human brain measured by positron emission tomography. Ito H; Takahashi H; Arakawa R; Takano H; Suhara T Neuroimage; 2008 Jan; 39(2):555-65. PubMed ID: 17962043 [TBL] [Abstract][Full Text] [Related]
10. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429 [TBL] [Abstract][Full Text] [Related]
11. Modeling dopamine system dysfunction in experimental animals. Hantraye P Nucl Med Biol; 1998 Nov; 25(8):721-8. PubMed ID: 9863556 [TBL] [Abstract][Full Text] [Related]
12. [The dopamine transporter: characterization and physiopathologic implications]. Thibaut F; Vaugeois JM; Petit M Encephale; 1995; 21(6):445-51. PubMed ID: 8674469 [TBL] [Abstract][Full Text] [Related]
13. The role of positron emission tomography imaging in movement disorders. Bohnen NI; Frey KA Neuroimaging Clin N Am; 2003 Nov; 13(4):791-803. PubMed ID: 15024962 [TBL] [Abstract][Full Text] [Related]
14. Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. Court JA; Piggott MA; Lloyd S; Cookson N; Ballard CG; McKeith IG; Perry RH; Perry EK Neuroscience; 2000; 98(1):79-87. PubMed ID: 10858614 [TBL] [Abstract][Full Text] [Related]
15. Imaging Dopaminergic Neurotransmission in Neurodegenerative Disorders. Wallert ED; van de Giessen E; Knol RJJ; Beudel M; de Bie RMA; Booij J J Nucl Med; 2022 Jun; 63(Suppl 1):27S-32S. PubMed ID: 35649651 [TBL] [Abstract][Full Text] [Related]
16. Dopamine synapse is a neuroligin-2-mediated contact between dopaminergic presynaptic and GABAergic postsynaptic structures. Uchigashima M; Ohtsuka T; Kobayashi K; Watanabe M Proc Natl Acad Sci U S A; 2016 Apr; 113(15):4206-11. PubMed ID: 27035941 [TBL] [Abstract][Full Text] [Related]
17. Neurodegenerative movement disorders: the contribution of functional imaging. Piccini P Curr Opin Neurol; 2004 Aug; 17(4):459-66. PubMed ID: 15247543 [TBL] [Abstract][Full Text] [Related]
18. Molecular imaging of movement disorders. Lizarraga KJ; Gorgulho A; Chen W; De Salles AA World J Radiol; 2016 Mar; 8(3):226-39. PubMed ID: 27029029 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological treatment with L-DOPA may reduce striatal dopamine transporter binding in in vivo imaging studies. Nikolaus S; Antke C; Hautzel H; Mueller HW Nuklearmedizin; 2016; 55(1):21-8. PubMed ID: 26642370 [TBL] [Abstract][Full Text] [Related]
20. Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts. Puschban Z; Scherfler C; Granata R; Laboyrie P; Quinn NP; Jenner P; Poewe W; Wenning GK Neuroscience; 2000; 95(2):377-88. PubMed ID: 10658617 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]